Journal of Natural Products · 2017 · 82 citations · 44 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAlzheimer DiseaseAmyloid FormationIn Vitro PharmacologyMolecular DockingStructure-activity Relationship AnalysisVirtual ScreeningAggregation InhibitorsAmyloid Beta AggregationCell-based Drug ScreeningDementia Drug DevelopmentInhibition Of Amyloid FormationPhenolic CompoundsProtein Aggregation InhibitionProtein Aggregation Inhibitors
Alzheimer's disease (AD) is the main cause of dementia in people over 65 years. One of the major culprits in AD is the self-aggregation of amyloid-β peptide (Aβ), which has stimulated the search for small molecules able to inhibit Aβ aggregation. In this context, we recently reported a simple, but effective in vitro cell-based assay to evaluate the potential antiaggregation activity of putative Aβ aggregation inhibitors. In this work this assay was used together with docking and molecular dynamics simulations to analyze the anti-Aβ aggregation activity of several naturally occurring flavonoids and phenolic compounds. The results showed that rosmarinic acid, melatonin, and o-vanillin displayed zero or low inhibitory capacity, curcumin was found to have an intermediate inhibitory potency, and apigenin and quercetin showed potent antiaggregation activity. Finally, the suitability of the combined in vitro cell-based/in silico approach to distinguish between active and inactive compounds was further assessed for an additional set of flavonols and dihydroflavonols.
44
2011 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2011 · 911 citations
Medicine, Geriatric Medicine, Population Health Sciences +16